SYMATESE wins CE mark for ESTYME hyaluronic acid-based injectable products

SYMATESE announced that they have received CE marking certification for their new line of hyaluronic acid-based injectable products, ESTYME®. This certification marks the start of an exciting journey: the European launch of the products is the first step in a broader international expansion that will also take the brand to the U.S., Chinese, and Brazilian markets by 2025.

With their unique approach to tissue regeneration and cutting-edge technology, the company is entering a €3 billion market! Their goal is to triple their revenue by 2028 and establish themselves as a leader in the industry.

Their next steps are to expand across Europe and the United States in partnership with Evolus Inc., which will complement its offering with the ESTYME® range alongside its already well-established neurotoxin in the U.S. market.